Tools   Select Another Resource Report Type

http://ranchobiosciences.com/gse27831/

Curated data set from gene expression profiles of 29 unique samples from uveal melanoma patients that were measured on Affymetrix microarray. In addition, expression of syntenin-1 was measured by RT-PCR and this data is also available in the study.

Proper citation: GSE27831 (RRID:SCR_003646) Copy   

•   Source: SciCrunch Registry

http://ranchobiosciences.com/gse20194/

Curated data set of gene expression data from 230 stage I-III breast cancers that were generated from fine needle aspiration specimens of newly diagnosed breast cancers before any therapy. The biopsy specimens were collected sequentially during a prospective pharmacogenomic marker discovery study between 2000 and 2008. These specimens represent 70-90% pure neoplastic cells with minimal stromal contamination. In the study, patients received 6 months of preoperative (neoadjuvant) chemotherapy including paclitaxel, 5-fluorouracil, cyclophosphamide and doxorubicin followed by surgical resection of the cancer.

Proper citation: GSE20194 (RRID:SCR_003645) Copy   

•   Source: SciCrunch Registry

http://ranchobiosciences.com/gse4698/

Curated data set where gene expression profiling was performed on 60 prospectively collected samples of children with first relapse of acute lymphoblastic leukemia enrolled on the relapse trial ALL-REZ BFM 2002 of the Berlin-Frankfurt-Muenster study group.

Proper citation: GSE4698 (RRID:SCR_003644) Copy   

•   Source: SciCrunch Registry

http://ranchobiosciences.com/gse4271/

Curated data set from a study that investigated 77 primary high-grade astrocytomas and 23 matched recurrences so that changes in gene expression related to both survival and disease progression can be identified. Samples in the study include WHO grade III and IV astrocytomas with a wide range of survival times.

Proper citation: GSE4271 (RRID:SCR_003643) Copy   

•   Source: SciCrunch Registry

http://www.stanford.edu/~rnusse/pathways/targets.html

A list of target genes of Wnt/beta-catenin signaling. Suggestions for additions are welcome. Direct targets are defined as those with Tcf binding sites and demonstrating that these sites are important.

Proper citation: Target genes of Wnt/beta-catenin signaling (RRID:SCR_007022) Copy   

•   Source: SciCrunch Registry

http://www.biobanks.se/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 6th, 2022. The biobank comprises paraffin blocks of surgical and autopsy tissue samples and corresponding histological slides as well as cytological material consisting of slides of vaginal smears, fine needle aspiration biopsies and exfoliative cytological material. The tissue samples date back until 1944 and most of the cytological samples until 1970. A subunit of the bank constitutes the National Tissue Microarray Centre. This center is supported by SWEGENE with the purpose to organize and construct tissue microarrays (TMA:s) for high throughput molecular pathology research on various kinds of tumors and other diseases. By linking the TMA.s to long-term and complete clinical follow-up data, prognostic and predictive studies will be facilitated. Biobank content: * Approximately 2,4 million paraffin blocks of surgical tissue specimens, * 1,1 million paraffin blocks of tissue samples from autopsies, * 3,8 million histological slides and * 1,6 million cytology slides. At present, the Tissue Microarray Centre includes: * A consecutive series of all invasive breast cancers (n=600) diagnosed in Malmo between 1988 and 1992. * All incident breast cancers within the Malmo Diet and Cancer cohort (n=400). * A subgroup of 600 pre-menopausal primary breast cancers within the nationwide, population-based randomized tamoxifen trial SBII:2. * 180 primary breast cancers from post-menopausal women included in a similar study. * A set of 120 extremely well characterized primary breast cancer samples with a clinical follow-up of 10 years. More than 40 relevant tumor biological parameters have been recorded in this material and it is therefore useful for a first screening of a marker in order to identify associations to other gene products. * 350 renal cell carcinomas (In collaboration with NUS). We provide researchers with state-of-the-art population based tissue microarrays with long-term and complete follow-up data on survival and treatment. With the TMA-technology, valuable biobank material will be preserved, allowing high throughput in-situ analyses of various tumors and other diseases with a minimal waste of tissue.

Proper citation: UMAS University Hospital - Biobanks of the Department of Clinical Pathology and Cytology (RRID:SCR_005957) Copy   

•   Source: SciCrunch Registry

https://pdc.cancer.gov/pdc/

Portal to make cancer related proteomic datasets easily accessible to public. Facilitates multiomic integration in support of precision medicine through interoperability with other resources. Developed to advance our understanding of how proteins help to shape risk, diagnosis, development, progression, and treatment of cancer. One of several repositories within NCI Cancer Research Data Commons which enables researchers to link proteomic data with other data sets (e.g., genomic and imaging data) and to submit, collect, analyze, store, and share data throughout cancer data ecosystem. PDC provides access to highly curated and standardized biospecimen, clinical, and proteomic data, intuitive interface to filter, query, search, visualize and download data and metadata. Provides common data harmonization pipeline to uniformly analyze all PDC data and provides advanced visualization of quantitative information. Cloud based (Amazon Web Services) infrastructure facilitates interoperability with AWS based data analysis tools and platforms natively. Application programming interface (API) provides cloud-agnostic data access and allows third parties to extend functionality beyond PDC. Structured workspace that serves as private user data store and also data submission portal. Distributes controlled access data, such as patient-specific protein fasta sequence databases, with dbGaP authorization and eRA Commons authentication.

Proper citation: Proteomic Data Commons (RRID:SCR_018273) Copy   

•   Source: SciCrunch Registry

https://portal.imaging.datacommons.cancer.gov

Portal for finding and analyzing cancer imaging data. Part of Cancer Research Data Commons to support cancer imaging research. Provides cloud based access to medical imaging data and library of analytical tools and workflows to share, analyze, and visualize multi modal imaging data from both clinical and basic cancer research studies.

Proper citation: NCI Imaging Data Commons (RRID:SCR_019127) Copy   

•   Source: SciCrunch Registry

https://datacommons.cancer.gov

Cloud based data science infrastructure that provides secure access to cancer research data from NCI programs and key external cancer programs. Serves as coordinated resource for public data sharing of NCI funded programs. Users can explore and use analytical and visualization tools for data analysis. Enables to search and aggregate data across repositories including Cancer Data Service, Clinical Trial Data Commons, Genomic Data Commons, Imaging Data Commons, Integrated Canine Data Commons, Proteomic Data Commons.

Proper citation: Cancer Research Data Commons (RRID:SCR_019128) Copy   

•   Source: SciCrunch Registry

http://ncim.nci.nih.gov/ncimbrowser/

A wide-ranging biomedical terminology database that covers most terminologies used by NCI for clinical care, translational and basic research, and public information and administrative activities. NCIm features: * Maps 4,000,000 terms from more than 75 sources into 2,000,000 biomedical concepts that represent their meaning. * Displays preferred terms, synonyms, definitions, and other information from each source. * Links to NCI Thesaurus and other related information sources. * Contains 22,000,000 cross-links between content elements. * Updated frequently by a team of biomedical terminology and subject matter experts. NCIm contains most public domain terminologies from the National Library of Medicine's UMLS Metathesaurus, as well as many other biomedical terminologies created by or of interest to NCI and its partners. Some propriety terminologies are included, with permission, and have restrictions on their use. The current version of the NCI Metathesaurus, based on the UMLS build 2013AA, covers up to National Cancer Institute Thesaurus, 13.12d. A viewer for the UMLS changes document can be downloaded.

Proper citation: NCI Metathesaurus (RRID:SCR_003565) Copy   

•   Source: SciCrunch Registry

http://www.tubafrost.org/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9, 2023. In this web site you will find the central European database of OECI-TuBaFrost collecting the information of biobanks or in the project support environment on human material; i.e., frozen tumor tissue specimens, pathology blocks, blood samples in different forms, cell lines, Tissue Micro Arrays, etc. Our goal is by centralizing the tumor tissues information to facilitate the search of doctors / researchers for tumor materials, which they need for their cancer research there with facilitating cancer research. OECI members only can participate in the OECI-TuBaFrost exchange platform, or those introduced by an OECI member. We are a group of pathology and research departments as well as bio-bankers in clinical based biobanking based in comprehensive cancer centers or hospitals with a competence in comprehensive cancer care across Europe. Each participating institute is involved in cancer research resulting in innovative procedures, new drugs, improved diagnosis and new insights in disease development. The overall result is better care and treatment for cancer patients. To maximize the scientific value of the human tissue samples, information about the clinical status of the patient in combination with the quality and type of samples is very important. A TuBaFrost electronic database will securely store all this information. Within the closed project supporting environments, the data collected will include: * Diagnosis - identification of the type of cancer * Type of tissue collected - the origin, i.e. breast, skin, colorectal * Quality of tissue collected - collection and storage details The tissue is stored in the hospital where the donor was diagnosed/treated. It stays there until it is used or sent to another hospital or research center within the TuBaFrost group. The electronic database will track samples throughout the network. The tissue is not sold. The exchange of tissue to other hospitals is regulated by a contract, which uses the national regulations of the country supplying the tissue. Tissue samples within the TuBaFrost collection will only be used for research, which has been approved by ethics committees. This ensures that the tissue is only used for the best quality research and only for the specific reasons given to the ethics committee.

Proper citation: OECI - Tubafrost: The European Human Frozen Tissue Bank (RRID:SCR_004280) Copy   

•   Source: SciCrunch Registry

http://www.rrcancer.ca/en/publique/accueil

An infrastructure to allow Quebec researchers to have at their disposal tumor banks and the services that support large scale research in genomics and proteomics. The database and the tissue bank of the research network was created to allow rapid access to biological samples and their clinical data. It is spread out over many hospital institutions (in Montreal, Quebec and Sherbrooke). The members of the RRCancer-BTD supply normal, benign and malignant samples from routine surgeries and blood tests. Blood and tissue samples are collected by the provincial biobanks on a regular basis and are coded, classified and stored. The samples can be supplied to a researcher either fresh or frozen or blocks of paraffin or on slices. The sharing of information and biological material is managed according to ethical rules and contributes to increasing the value of research in Quebec. The network has mobilized a significant number of researchers in the area of cancer that unite their efforts to pursue high caliber multidisciplinary research. They are a group of researchers from many different Qu��bec Universities all working in the branch of cancer research. They are located in four hospital centers in Quebec, namely the University of Montreal Hospital Centre (CHUM), the University of Quebec Hospital Centre (CHUQ), the University of Sherbrooke Hospital Centre (CHUS) and the McGill University Hospital Centre (CUSM), as well as in the affiliated research and university centers (Sacr��-Coeur, Maisonneuve-Rosemont and the Montreal Jewish Hospital). The collaborative efforts created and maintained in this network have allowed transfer of knowledge and the sharing of cutting edge technologies. RRCancer favors multidisciplinary cancer research in both fundamental and clinical scopes. The network is based on the desire researchers to work together to prevent cancer and improve therapeutic strategies, all the while continuing the very important task of raining new specialists and graduate students.

Proper citation: Cancer Research Network of the FRSQ (RRID:SCR_004225) Copy   

•   Source: SciCrunch Registry

http://www.ibbl.lu/

An independent, not-for-profit biobanking and biotechnology foundation designed to facilitate new, high quality medical research. The IBBL collects, stores, and analyzes biological samples and associated data, which are then made available to research organizations investigating new treatments for diseases. It houses a biospecimen collection and biorepository that contains high quality tissues and maintains quality control of the specimens and the clinical data associated with the tissue samples, while maintaining biobanking ethical standards. It also provides biorefinery analyses and research services that can make analytes from tissues (e.g. DNA, RNA and protein), maintains technology for high throughput gene sequencing and gene expression, and conducts biospecimen research. An informatics platform maintains the clinical and biospecimens data in a secure fashion for additional analysis. Samples are collected by IBBL personnel from hospitals in a targeted manner. The IBBL collaborates with research and health organizations in North America, Europe and the Middle East, and with the major international biobanking societies.

Proper citation: Integrated Biobank of Luxembourg (RRID:SCR_004211) Copy   

•   Source: SciCrunch Registry

http://www.itor-ghs.org/biorepository.php

From the type of mutation causing cancer to specific gene expression levels, genetic biomarkers are becoming an indispensable tool for developing new treatment models for cancer. The ITOR Biorepository Services tissue bank initiatives are critical to the continued development of an organized research infrastructure that will attract leading biotechnology and pharmaceutical companies interested in developing the next generation of cancer therapies. Ultimately, by linking the laboratory and clinical settings through innovative research investigations, USC, Greenville Hospital System University Medical Center, and private partners can identify the most novel ways to find and couple these biomarkers to patient drug trials and eventually, the most effective treatments & cures for cancer. The ITOR Biorepository Services Department ����?����������?? in conjunction with the Greenville Hospital System''s surgical oncologists, pathologists and staff ����?����������?? have developed tissue bank sample processing guidelines for frozen tissue, fresh tissue and peripheral blood and include flash freezing in liquid nitrogen within 15 minutes of harvest to maximize cell viability for basic science research. The department has a dedicated staff, including two research nurses and a data coordinator, which facilitate the logistics of tissue handling and submit outcomes data on participating patients. The ITOR Biorepository staff is in the process of adopting a universal consent for all patients of the Greenville Hospital System to have the option of donating excess tissue for research, should they desire. ITOR of GHS has several tissue-based patient initiatives & programs under development and ongoing. At the forefront of cancer care are two specific programs, Total Cancer Care and Caris Target Now.

Proper citation: ITOR Biorepository Services (RRID:SCR_004191) Copy   

•   Source: SciCrunch Registry

http://www.liv.ac.uk/ltb/

THIS RESOURCE IS NO LONGER IN SERVICE, documented May 10, 2017. It has been incorporated with the LBIH Biobank. The Liverpool Tissue Bank (LTB) collects biological samples (tissue surplus to diagnostic requirement and blood) from patients undergoing surgery or biopsy procedure for the treatment and diagnosis of a wide variety of medical conditions. The main focus of the LTB is collecting samples from patients where cancer is a confirmed or likely diagnosis. These samples are banked to provide an invaluable resource for research groups investigating the molecular mechanisms involved in a range of medical conditions with the aim of devising new treatments and therapies. The Liverpool Tissue Bank (LTB) was formerly known as the Cancer Tissue Bank Research Centre (CTBRC) and changed to the LTB in late 2009. The Tissue Bank was established in 1991 from a charitable donation by the Candis Club, the charitable arm of Candis Magazine. It is a University of Liverpool resource located within the Department of Pathology, School of Cancer Studies. The LTB operates a cost recovery scheme where a charge is made to researchers to cover the costs involved in the collection, storage and processing of biosamples.

Proper citation: Liverpool Tissue Bank (RRID:SCR_004143) Copy   

•   Source: SciCrunch Registry

http://www.mycancergenome.org/

A freely available online personalized cancer medicine knowledge resource for physicians, patients, caregivers and researchers that gives up-to-date information on what mutations make cancers grow and related therapeutic implications, including available clinical trials. It is a one-stop tool that matches tumor mutations to therapies, making information accessible and convenient for busy clinicians.

Proper citation: My Cancer Genome (RRID:SCR_004140) Copy   

•   Source: SciCrunch Registry

http://www.startthecure.com/clinical_tumor_bank.php

Biospecimen repository for tumor specimens, available to all researchers actively engaged in cancer research whether they are in University, Academic, or Pharmaceutical industry, with a goal to accelerate the discovery and development of new agents for the treatment and cure of cancer. The START tumor bank was created to make tumor tissue gifted by patients receiving care or treatment at The START Center available to all researchers involved in developing a better understanding of the biology of cancer or those engaged in the discovery of new therapies. The START Tumor Bank is a department within the PK Department and handles skin and tumor biopsies required by clinical trial protocols. A member of the PK Department is present during biopsy procedures for immediate processing of the sample for the trial. Additionally, the Tumor Bank collects and banks the tumor tissues of patients who consent. This tissue is then stored for future use by researchers developing new therapies.

Proper citation: START Tumor Bank (RRID:SCR_004258) Copy   

•   Source: SciCrunch Registry

https://www.bips-institut.de/en/research/cancer-registry.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9, 2023. A population based database collecting incident cases of cancer diagnosed since January 1998 in the population of the Federal state of Bremen. The Registry provides data for the analysis of * age specific time trends and geographical patterns of cancer incidence in men and women * cancer causes (e.g. work-related, environmental and personal risk factors) * epidemiological evaluation of screening programs * survival analysis of cancer patients. Since the incidence year of 2001, the Registry has a completeness level of > 95 %, based on expected values provided by the Robert Koch Institute.

Proper citation: Bremen Cancer Registry (RRID:SCR_004093) Copy   

•   Source: SciCrunch Registry

http://www.umassmed.edu/cancercenter/tissuebank/index.aspx

The UMass Cancer Center Tissue and Tumor Bank is a dynamic tissue procurement service: Collection, Storage, Annotation, and Distribution of Human Biologic Specimens. Our goal is to facilitate basic science, clinical research and translational studies by providing researchers with the ability to obtain and study human tissues using a dynamic collection, storage, annotation, and distribution service. * Fresh, diseased tissue is collected and processed immediately after surgery. ** When possible, surrounding healthy tissue is collected as a matched normal control. ** Anonymous, de-identified clinical and pathologic data are linked to the specimens in a secure database. * Bone marrow and blood specimens are collected and available as fresh cell isolates, frozen cell isolates or unprocessed. * A variety of services are available including routine histology, fresh tissue for cell culture, frozen sections, as well as DNA and RNA extraction. * Specific study needs can be met. * Consultation during study design is available and recommended. Contact Us * Assistance in the IRB approval process is offered. ** New: IRB approval is required only if you need identifiable private clinical information and/or patient follow-up for your study. The UMass Cancer Center Tissue and Tumor Bank is an open access biorepository. Specimens are available to investigators both internal and external to UMass. The Tumor Bank ships specimens to researchers worldwide. Please contact us to determine if we have specimens that meet your research needs.

Proper citation: UMass Cancer Center Tissue and Tumor Bank (RRID:SCR_004447) Copy   

•   Source: SciCrunch Registry

https://htrn.osu.edu/Services/Biorepository/Pages/default.aspx

The HTRN biospecimen bank is comprised of samples for the Ohio State University Cancer and Leukemia Group B Pathology Coordinating Office (CALGB-PCO) and the Ohio State University Midwestern Division of the Cooperative Human Tissue Network (CHTN). The CALGB-PCO banks biospecimens donated by patients enrolled in clinical trials. Samples can include tumor and normal tissue, plasma, serum, whole blood and white blood cells and urine. All of these samples are used later in correlative studies. The Midwestern Division of the CHTN stores a temporary biospecimen bank of tumor and normal tissue, tissue slides and paraffin embedded tissue blocks for research investigators throughout the country and Canada who are trying to find a cure for cancer. As part of the HTRN biospecimen bank, a Rees Scientific equipment monitoring system helps to secure the integrity and quality of samples stored in the biorepository. Scientific research within the HTRN is currently underway to determine the best methods in tissue storage for long term use. The NCI First-Generation Guidelines for NCI-Supported Biorepositories and the NCI Best Practices for Biospecimen Resources are continuously reviewed and adapted by the HTRN.

Proper citation: Ohio State Biorepository (RRID:SCR_004714) Copy   

•   Source: SciCrunch Registry